Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Maurice Winn who wrote (2436)	8/16/1998 9:15:00 AM
From: PDavid	Read Replies (1) \| Respond to of 3702

I must agree with Terry. The Yahoo thread has become far more informative than this thread. Data is not everything. I already own the stock, data will be publicized when the company is good and ready. This thread has practically disappeared when it comes to valuable information. Usually a battle of egos is what one can expect these days, along with a nice smug dig at the Yahoo posters, which is inappropriate. Davis still posts great information, so my comments are not directed to him. Bottom line,if someone is too lazy to wade through the Yahoo posts for good information, thats your problem. But don't hide behind some elitist attitude as being the reason for preferring SI. And now, unionpride is quite informative, as well as the ICQ chat. Again, if one is too lazy to surf, fine, but leave it at that. Its your loss. I read and post on both threads. This one gives me limited information, at best. Maurice, as a side note, investorcg, boblll, terry, berblady, etc. etc. etc. provide excellent information over there. Give it a shot, huh? Phil

To: Maurice Winn who wrote (2436)	8/16/1998 5:47:00 PM
From: Terry D.	Read Replies (1) \| Respond to of 3702

is this data? CLINICAL OUTCOME FOLLOWING MULTIDOSE SALVAGE THERAPY WITH ONCOLYMTM IN PATIENTS WITH INTERMEDIATE OR HIGH GRADE NON-HODGKIN'S B-CELL LYMPHOMA (NHL): A RETROSPECTIVE EVALUATION. J. Oliver, G. DeNardo, S. DeNardo. Techniclone Corporation, University of California-Davis. Oncolym is currently in clinical development as a possible treatment of NHL. A retrospective analysis of 33 patients with recurrent or refractory intermediate- or high-grade NHL treated with multiple doses ranging from 10--100 mCi/m2 was performed. All patients were classified Ann Arbor stage 3--4 and the majority had extranodal disease. Patients were stratified by initial dose into 4 groups; Grp1 = 10--24.5 mCi/m2, Grp2 = 24.6--39.5 mCi/m2, Grp3 = 39.6--74.5 mCi/m2, and Grp4 = >74.6 mCi/m2. An objective response was the combined frequency of either a complete response (CR) or partial response (PR). Duration of response was measured from the first CT evidence of response to disease progression or treatment with another salvage therapy. Overall, 51.5% (17/33) patients responded to multidose therapy. The mean durability of the response was 12.6 ñ 12.3 months (range 1.5--44) in these patients. Patients in Grp1 (3 high-grade (HG) and 4 intermediate-grade (IG)) demonstrated a 25% (2/8) objective response with an average durability of 10 months. Grp2 patients (2 HG and 8 IG) had a 70% (7/10) response rate for a average durability of 16.8 months. Patients in Grp3 (2 HG and 5 IG) showed a 43% (3/7) response with a durability of 4 months. The patients in Grp4 (1 HG and 7 IG) had a 62% (5/8) objective response lasting an average of 12.9 months. Durability was clinically significant in all groups except Grp3. The prolonged durability in these patients with severe refractory disease may be a cumulative dose effect associated with repeated therapeutic doses. Thrombocytopenia was the dose limiting toxicity and occurred in 42% of the patients treated across all doses, but resolved without sequelae. In conclusion, Oncolym appears to produce clinical meaningful responses following multiple doses with average durability over 12 months. Haven't found much on TNT yet. Still searching. Terry